Phagoburn

Phagoburn is a current European Union financed clinical study focused on testing the medical uses of bacteriophage for treating wounds. The main objective of Phagoburn is to assess the safety, effectiveness and pharmacodynamics of two therapeutic phage cocktails to treat E. coli and P. aeruginosa burn wound infections.[1][2] It is taking place in France, Belgium, and Switzerland. Pherecydes Pharma is the main sponsor of the trial.[3]

See also

Phage therapy

References

  1. ↑ Brussow, H. (23 November 2013). "Editorial Commentary: Phage Therapy: Quo Vadis?". Clinical Infectious Diseases. 58 (4): 535–536. doi:10.1093/cid/cit776.
  2. ↑ Gross, Michael (June 2014). "Phage therapies for plants and people". Current Biology. 24 (12): R541–R544. doi:10.1016/j.cub.2014.05.064.
  3. ↑ Harper, David; Parracho, Helena; Walker, James; Sharp, Richard; Hughes, Gavin; Werthén, Maria; Lehman, Susan; Morales, Sandra (25 June 2014). "Bacteriophages and Biofilms". Antibiotics. 3 (3): 270–284. doi:10.3390/antibiotics3030270.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.